www.tajpharma.com

Administered once daily,
RIVETROX™ offers an effective, short six-day course of therapy.

I/V to oral once-daily
RIVETROX™
(tedizolid phosphate)200mg

NEW ANTIBIOTIC I/V to oral once-daily

RIVETROX™

(tedizolid phosphate)200mg

RIVETROX™ (tedizolid phosphate) received FDA approval on June 20, 2014.
RIVETROX™ treats adult acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA), which has been categorized by the U.S. Centers for Disease Control and Prevention (CDC) as a serious public health threat.

Indication

RIVETROX™ (tedizolid phosphate) is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible isolates of the following Gram-positive microorganisms: Staphylococcus aureus (including methicillin-resistant [MRSA] and methicillin-susceptible [MSSA] isolates), Streptococcus pyogenes, and Streptococcus anginosus group (including Streptococcus anginosus, Streptococcus intermedius and Streptococcus constellatus).

RIVETROX™ is a once daily oxazolidinone being developed for both intravenous (I.V.) and oral administration for the treatment of serious infections caused by certain Gram-positive bacteria, including those caused by methicillin-resistant Staphylococcus aureus (MRSA). The Company's New Drug Application (NDA) submission to the FDA for RIVETROX™ is based on positive data from two global Phase 3 clinical studies, which met the primary and secondary endpoints defined by the FDA and European Medicines Agency (EMA).

RIVETROX™ is administered once daily for 6 days, and is available in intravenous and oral formulations,.

Note: Nausea, headache, diarrhea, vomiting, and dizziness were the most common side effects to surface in the clinical trials.

Food and Drug Administration (FDA) approved .Prescription Only (POM)

A Taj Pharma"India Product